

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊 生 物 科 技 有 限 公 司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

INSIDE INFORMATION COURT ORDER

This announcement is made by the board of directors (the “**Board**”) of Wai Chun Bio-Technology Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 23 February 2026, the Company received a sealed Judgment (the “**Judgment**”) from the Court of First Instance of the High Court of the Hong Kong Special Administrative Region (the “**High Court of Hong Kong**”) dated 13 February 2026 against the Company and Wai Chun Group Holdings Limited (the “**First Defendant**”). The Judgment states that (i) the Company and the First Defendant do each pay Island Sky Limited (the “**Plaintiff**”) the sum of HK\$2,672,193.60 and the interest on the sum of HK\$2,672,193.60 at the rate of 1% above HSBC prime rate per annum from 7 September 2023 to the date hereof and thereafter at judgment rate until payment; and (ii) costs of this action, with certificate for counsel, be paid by the Company and the First Defendant to the Plaintiff summarily assessed at HK\$111,000.00 payable forthwith.

The sum of HK\$2,672,193.60 is being 50% of the mesne profits, rent and rate, management and air-conditioning charges for the period from 16 September 2022 to 27 April 2023 of the whole premises which is located at 13th Floor of Tower II, Admiralty Centre, No. 18 Harcourt Road, Hong Kong.

FURTHER ACTION TO BE TAKEN BY THE COMPANY

The Board is in view of that the Plaintiff was claiming for excessive mesne profits which is much higher than the market comparables and the Company and the First Defendant have lodged a Notice of Appeal with the High Court of Hong Kong as at the date of this announcement.

In view of the above, the Company is in the course of seeking legal advice for determining the possible actions in respect of the Judgment to protect the interests of the Company and its shareholders, including but not limited to, apply for a stay of execution and submit evidence for the appeal.

The Company will make further announcement(s) to keep its shareholders and investors informed of any significant developments in relation to the Judgment as and when appropriate.

By order of the Board
Wai Chun Bio-Technology Limited
LAM KA CHUN
Chairman

Hong Kong, 25 February 2026

As at the date of this announcement, the Board consists of one executive director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer), and three independent non-executive directors, namely Mr. Wong Po Keung, Ms. Xu Huiling and Mr. Wang Ziniu.